KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Current Leases (2023 - 2025)

Biocryst Pharmaceuticals' Current Leases history spans 3 years, with the latest figure at $1.3 million for Q4 2025.

  • For Q4 2025, Current Leases fell 28.5% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $1.3 million, down 28.5%, while the annual FY2025 figure was $1.3 million, 28.5% down from the prior year.
  • Current Leases reached $1.3 million in Q4 2025 per BCRX's latest filing, down from $1.4 million in the prior quarter.
  • In the past five years, Current Leases ranged from a high of $2.5 million in Q2 2023 to a low of $392000.0 in Q2 2025.
  • Average Current Leases over 3 years is $1.6 million, with a median of $1.7 million recorded in 2024.
  • Peak YoY movement for Current Leases: surged 73.44% in 2024, then tumbled 61.79% in 2025.
  • A 3-year view of Current Leases shows it stood at $1.1 million in 2023, then soared by 73.44% to $1.8 million in 2024, then decreased by 28.5% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for BCRX's Current Leases are $1.3 million (Q4 2025), $1.4 million (Q3 2025), and $392000.0 (Q2 2025).